Investors

SEC Filings

SEC Filings

Filing date	Form	Description	View
April 25, 2024	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001517022-24-000045.pdf 0001517022-24-000045.rtf 0001517022-24-000045.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
March 1, 2022	POSASR	POSASR	0001193125-22-061326.pdf 0001193125-22-061326.rtf 0001193125-22-061326.xls View HTML
March 1, 2022	POS AM	Post-effective amendment to an S-Type filing	0001193125-22-061620.pdf 0001193125-22-061620.rtf 0001193125-22-061620.xls View HTML
April 13, 2015	S-3/A	Pre-effective amendment to an S-3 filing	0001193125-15-126906.pdf 0001193125-15-126906.rtf 0001193125-15-126906.xls View HTML
October 25, 2018	S-4/A	Pre-effective amendment to an S-4 filing	0001193125-18-307890.pdf 0001193125-18-307890.rtf 0001193125-18-307890.xls View HTML
October 29, 2018	S-4/A	Pre-effective amendment to an S-4 filing	0001193125-18-309873.pdf 0001193125-18-309873.rtf 0001193125-18-309873.xls View HTML
April 15, 2020	PRER14A	Proxy soliciting materials. Revised preliminary material	0001193125-20-107370.pdf 0001193125-20-107370.rtf 0001193125-20-107370.xls View HTML
May 12, 2014	10-Q	Quarterly report which provides a continuing view of a company's financial position	0001193125-14-193535.pdf 0001193125-14-193535.rtf 0001193125-14-193535.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
August 11, 2014	10-Q	Quarterly report which provides a continuing view of a company's financial position	0001193125-14-303848.pdf 0001193125-14-303848.rtf 0001193125-14-303848.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
November 10, 2014	10-Q	Quarterly report which provides a continuing view of a company's financial position	0001564590-14-005335.pdf 0001564590-14-005335.rtf 0001564590-14-005335.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Data provided by Kaleidoscope.

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax